What We're Reading: Page 118
Industry reads hand-picked by our editors
Jul 13, 2022
Jul 12, 2022
-
Bloomberg Law
Drug Pricing Plan Faces Industry Gripes as Senate Reconvenes
-
Associated Press
Over-the-counter birth control? Drugmaker seeks FDA approval
-
Evaluate Vantage
Are we there yet?
-
Healthcare Dive
Tracking state abortion bans in the US
Jul 11, 2022
-
The New York Times
The U.S. May Be Losing the Fight Against Monkeypox, Scientists Say
-
Chemical & Engineering News
UK government chaos yields uncertainty for scientists
-
Fierce Biotech
Sanofi preps hemophilia duo for patients seeking as 'normal a life as possible'
-
Reuters
EU recommends second COVID booster for over-60s
Jul 08, 2022
-
The Washington Post
Former Theranos executive Sunny Balwani convicted on 12 fraud counts
-
The New York Times
Officials Balked at a Drug Company’s Tax Shelter. Auditors Approved It Anyway.
-
The Boston Globe
Cambridge microbiome company looks beyond fecal transplants
Jul 07, 2022
-
The Guardian
London stock market listing of up to £45bn looms as GSK investors vote for demerger
-
Life Sci VC
Surprising Resilience Of Private VC-Backed Biotech Markets
-
Politico
World’s Covid vaccine, drugs equity program set to wind down this fall
-
Pharmaceutical Technology
Is biotech facing a long bear market?
Jul 06, 2022
-
BioCentury
Follow-ons perk up in June, but still well shy of last year’s haul
-
Nature
Revisiting checkpoint blockade
-
Business Insider
Genomics giant Illumina is looking beyond the sequencing box. But investors aren't sold on CEO Francis deSouza's 'legacy-defining' $8 billion gamble.
-
The Wall Street Journal
Little-Known Abortion Pill Maker Faces Scrutiny
Jul 05, 2022
-
The Financial Times
Covid vaccines: how can immune imprinting help experts to rethink jabs?
-
STAT
VC deals and valuations begin falling apart amid biotech’s stock shock
-
BioCentury
After Forty Seven takeout, MacQuitty finding ‘freedom’ with Lightspeed team
-
Bloomberg
GSK’s New Vaccine Hire Looks Beyond Covid in Quest for Next Hit
Previous
